- Home
- TKNO vs STRO Comparison
TKNO vs STRO Comparison
Compare TKNO & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TKNO
- STRO
- Stock Information
- Founded
- TKNO 1996
- STRO 2003
- Country
- TKNO United States
- STRO United States
- Employees
- TKNO N/A
- STRO N/A
- Industry
- TKNO Medicinal Chemicals and Botanical Products
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TKNO Health Care
- STRO Health Care
- Exchange
- TKNO Nasdaq
- STRO Nasdaq
- Market Cap
- TKNO 244.7M
- STRO 292.6M
- IPO Year
- TKNO 2021
- STRO 2018
- Fundamental
- Price
- TKNO $5.91
- STRO $2.89
- Analyst Decision
- TKNO Buy
- STRO Strong Buy
- Analyst Count
- TKNO 2
- STRO 7
- Target Price
- TKNO $5.00
- STRO $12.14
- AVG Volume (30 Days)
- TKNO 269.2K
- STRO 596.9K
- Earning Date
- TKNO 11-07-2024
- STRO 11-13-2024
- Dividend Yield
- TKNO N/A
- STRO N/A
- EPS Growth
- TKNO N/A
- STRO N/A
- EPS
- TKNO N/A
- STRO N/A
- Revenue
- TKNO $36,347,000.00
- STRO $160,955,000.00
- Revenue This Year
- TKNO $3.56
- STRO N/A
- Revenue Next Year
- TKNO $13.31
- STRO N/A
- P/E Ratio
- TKNO N/A
- STRO N/A
- Revenue Growth
- TKNO N/A
- STRO 230.90
- 52 Week Low
- TKNO $1.16
- STRO $2.13
- 52 Week High
- TKNO $7.92
- STRO $6.13
- Technical
- Relative Strength Index (RSI)
- TKNO 44.25
- STRO 32.85
- Support Level
- TKNO $6.15
- STRO $4.01
- Resistance Level
- TKNO $7.92
- STRO $4.60
- Average True Range (ATR)
- TKNO 0.69
- STRO 0.36
- MACD
- TKNO -0.17
- STRO -0.06
- Stochastic Oscillator
- TKNO 0.50
- STRO 3.93
About TKNO Alpha Teknova Inc.
Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its product offerings include pre-poured media plates for cell growth and cloning, liquid cell culture media and supplements for cellular expansion, and molecular biology reagents for sample manipulation, resuspension, and purification. It derives maximum revenue from United States.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.